Speaker(s): 

Adrianna Aziz, Pharmacy Intern Technician, Staff Member, Geisinger - has nothing to disclose.

Brodey Persun, Pharmacy Intern Technician, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Sarah F. Hale, PharmD, BCPPS, Director of Pharmacy, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Evaluate the impact of discontinuing empirical antibiotics early in pediatric oncology patients with high-risk febrile neutropenia on antimicrobial stewardship in comparison to standard extended treatment. 
• Discuss primary and secondary outcomes and their application to clinical practice.
• Describe the role of finerenone in patients with type 1 diabetes and chronic kidney disease.
• Identify the benefits associated with the use of finerenone in patients with type 1 diabetes and chronic kidney disease. 
• Recall adverse effects associated with the use of finerenone in patients with type 1 diabetes and chronic kidney disease. 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brian Simpkins, PharmD, Jessica Milheim, CPhT, Clara Bishay, PharmD, and Simran Kaur, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.